학술논문

TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.
Document Type
article
Source
Acta neuropathologica. 127(3)
Subject
Humans
Amyotrophic Lateral Sclerosis
Genetic Predisposition to Disease
Intercellular Signaling Peptides and Proteins
Proteins
Membrane Proteins
Nerve Tissue Proteins
Cohort Studies
Age Factors
Age of Onset
DNA Repeat Expansion
Genotype
Heterozygote
Polymorphism
Single Nucleotide
Alleles
Adult
Aged
Aged
80 and over
Middle Aged
Female
Male
Frontotemporal Lobar Degeneration
C9orf72 Protein
Progranulins
Rare Diseases
Aging
Neurosciences
Alzheimer's Disease Related Dementias (ADRD)
Brain Disorders
Neurodegenerative
Prevention
Genetics
Dementia
Frontotemporal Dementia (FTD)
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Acquired Cognitive Impairment
Aetiology
2.1 Biological and endogenous factors
Neurological
TMEM106B
C9orf72
Frontotemporal dementia
Frontotemporal lobar degeneration
Amyotrophic lateral sclerosis
Genetic modifier
Clinical Sciences
Neurology & Neurosurgery
Language
Abstract
Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis, and may be the most common genetic cause of both neurodegenerative diseases. Genetic variants at TMEM106B influence risk for the most common neuropathological subtype of FTLD, characterized by inclusions of TAR DNA-binding protein of 43 kDa (FTLD-TDP). Previous reports have shown that TMEM106B is a genetic modifier of FTLD-TDP caused by progranulin (GRN) mutations, with the major (risk) allele of rs1990622 associating with earlier age at onset of disease. Here, we report that rs1990622 genotype affects age at death in a single-site discovery cohort of FTLD patients with C9orf72 expansions (n = 14), with the major allele correlated with later age at death (p = 0.024). We replicate this modifier effect in a 30-site international neuropathological cohort of FTLD-TDP patients with C9orf72 expansions (n = 75), again finding that the major allele associates with later age at death (p = 0.016), as well as later age at onset (p = 0.019). In contrast, TMEM106B genotype does not affect age at onset or death in 241 FTLD-TDP cases negative for GRN mutations or C9orf72 expansions. Thus, TMEM106B is a genetic modifier of FTLD with C9orf72 expansions. Intriguingly, the genotype that confers increased risk for developing FTLD-TDP (major, or T, allele of rs1990622) is associated with later age at onset and death in C9orf72 expansion carriers, providing an example of sign epistasis in human neurodegenerative disease.